HIV-associated Tuberculosis: Clinical Case

S. S. Sleptsova¹*, N. A. Gulyaeva¹, P. S. Dyachkovskaya¹, V. K. Semenova¹, M. V. Egorova¹, L. I. Petrova¹, G. A. Krichko¹, M. N. Andreev¹, N. N. Sofronova², M. K. Vinokurova³, O. E. Dogorova³

¹M. K. Ammosov North-Eastern Federal University, Yakutsk, the Sakha Republic, Russia
²PKZ SPID I IZ, Perm, Russia
³Yakut NPZ “Ftiziatriia”, Yakutsk, the Sakha Republic, Russia

Abstract

This case report presents a 35-year-old female who presented with HIV-associated multidrug-resistant tuberculosis. Resistant tuberculosis in HIV-infected patients with immunodeficiency is extremely difficult for effective treatment. Nevertheless, our clinical case showed that the cure of tuberculosis is possible in the late stages of HIV infection with the correct choice of treatment tactics, taking into account the resistance of MBT with the subsequent use of antiretroviral therapy. The progression of HIV infection, against the background of the effective antituberculous therapy, was associated with the patient’s refusal to treat the underlying disease. (International Journal of Biomedicine. 2017;7(3):257-259.)

Key Words: human immunodeficiency virus • multidrug-resistant tuberculosis • antiretroviral therapy • antituberculous therapy

Abbreviations

AIDS, acquired immune deficiency syndrome; ARVT, antiretroviral therapy; CHC, chronic hepatitis C; HIV, human immunodeficiency virus; MBT, Mycobacterium tuberculosis; MDR-TB, multidrug-resistant tuberculosis; RS(Y), the Republic of Sakha (Yakutia); TB, tuberculosis.

Introduction

According to UNAIDS, there were approximately 36.7 million people worldwide living with HIV/AIDS at the end of 2015. An estimated 2.1 million individuals worldwide became newly infected with HIV in 2015.(1) Since the beginning of the epidemic, more than 70 million people have been infected with the HIV virus and about 35 million people have died of HIV.(2)

However, between 2000 and 2015, the number of new HIV infections in the world decreased by 35% and the AIDS-related death rate decreased by 28%, which saved the lives of 8 million people. On the contrary, in the Russian Federation, the number of HIV-infected people is increasing annually.(3) As of December 31, 2016, according to official data, 103,438 new HIV infections among the citizens of Russia were reported, which is 5.3% more than in 2015. The total number of reported cases of HIV infection among citizens of Russia has reached more than 1.1 million people, of whom 243,836 (21.8%) died from various causes. According to the data of the Yakut Republican Center for AIDS Prevention and Control, 2,022 HIV-infected persons have been registered since 1996 in RS(Y), and for the 6 months of 2017, 97 new cases of HIV infection were detected.

Along with HIV infection, Russia is one of 22 countries with a high burden of TB (1990−2014). In 2014, according to WHO, the prevalence rate of TB in Russia was 109[49–192] per 100,000 population, and HIV prevalence in incident TB cases was 4.6[3.8–5.3]%.

In RS(Y), 827 persons with HIV infection are currently registered, and 180 of them receive preventive therapy against
The patient refused ARVT.

CD4 counts of >289 cells/µL, RNA-HIV - 627,000 copies/ml.

At a repeated examination on August 24, 2016, the diagnosis was as follows: «HIV infection, stage 4B; AIDS. Cytomegalovirus infection; and the Epstein-Barr infection. CHC».

Complaints: a fever of 39 °C, abdominal pain, loose stools 1-2 times a day, marked weakness, cough, and weight loss. Health deteriorated during the last month, when these symptoms appeared.

Objective data: General condition was of moderate severity. Consciousness was preserved. The position in bed was passive. Skin was clean, dry, and pale. Local cyanosis and rash were absent. Lips were covered with crusts. Sclera of the eyes was a normal color. Subcutaneous fatty tissue was poorly developed. Edemas and bedsores were not present. Submandibular, cervical and inguinal lymph nodes were enlarged to 0.5 cm, dense, and painless. Throat was slightly hyperemic, tonsils not enlarged. The frequency of respiratory movements was 18 per minute. During auscultation, wheezing was not present. Heart sounds were rhythmical, muffled. Abdomen was soft, sensitive along the intestine, peristalsis preserved. The liver edge had a soft-elastic consistency. Spleen was not enlarged. The stool was regular and liquid; color was brown without pathological impurities. Urination was free, painless. Diuresis was adequate. Neurological status: meningeal symptoms were absent.

Laboratory test data: The total blood test (08.25.16): leukocytes - 3.36×10⁹/l, erythrocytes - 5.5×10¹²/l, hemoglobin - 137 g/l, hematocrit - 39.3%, lymphocytes - 8%, monocytes - 8.3%, neutrophils - 82.5%, eosinophils - 1.2%, basophils - 0%, platelets - 89×10⁹/l, ESR - 32 mm/h.

Biochemical blood test (08.25.16): albumin - 34.5 g/l, ALT – 10 U/L, AST - 21.9 U/L, total bilirubin - 4 µmol/l, cholesterol - 2.01 mmol/l, creatinine - 79 µmol/l, glucose - 4.78 mmol/l, total protein - 80.9 g/l, urea - 4 mmol/l.

Cytomegalovirus (CMV) and Epstein Barr Virus (EBV) were detected in PCR (07.21.16). In PCR (07.21.16), the number of HIV RNA copies was 2, 400, 000 copies/ml.

Immunological examination of blood (07.19.16): leukocytes - 6.2×10⁹/l, lymphocytes 10% (19-37), CD3 - 41% (60-80), CD4 - 9% (55 cells/ml), SD8 - 30% (16-39).

EIA (08.25.2016): HbsAg - negative, anti-HBcorIgM - negative, anti-HbsAg - negative, HBeAg - negative, anti-HDV - negative, anti-HCV - positive, core (+), NS (-), anti-HCV IgM - negative.

CT chest (08.25.16): the disseminated lung process.

Ultrasound of the abdominal cavity (08.25.16): moderate lymphadenopathy, diffusive changes in the liver.

Blood for sterility and blood culture (08.26.16) was negative.

Smear from fauces for candidiasis (08.26.16): Candida albicans >1×10⁹/ml, sensitive to nystatinum.

PCR (08.26.16): CMV DNA was not detected, HSV RNA was not detected.

Sputum smear on MBT by the bactec method (08.29.16): MBTs were detected and resistant to streptomycin, isoniazid, rifampicin, kanamycin, and capreomycin. All sputum cultures were negative from September to December 2016.

Case report

A 35-year-old woman with the antibodies to HIV infection detected in June 2011 was registered in the Yakutsk AIDS-Center in 2012. The infection was associated with intravenous drug use for 5 years. CHC was detected in 2012, but the antiviral treatment for CHC was not received.

In 2013, she was hospitalized in the infectious department of YaGKB with a diagnosis of active cytomegalovirus infection on the background of HIV-infection stage 4B. She had a fever of 39 °C, abdominal pain, a loose stool 1-2 times a day, and general pronounced weakness. At the examination, CD4 counts of >289 cells/µL, RNA-HIV - 627,000 copies/ml. The patient refused ARVT.

At a repeated examination on August 24, 2016, the diagnosis was as follows: «HIV infection, stage 4B, the progression phase in the absence of ARVT; AIDS. Cytomegalovirus infection; and the Epstein-Barr infection. CHC».

Complaints: a fever of 39 °C, abdominal pain, loose stools 1-2 times a day, marked weakness, cough, and weight loss. Health deteriorated during the last month, when these symptoms appeared.

Objective data: General condition was of moderate severity. Consciousness was preserved. The position in bed was passive. Skin was clean, dry, and pale. Local cyanosis and rash were absent. Lips were covered with crusts. Sclera of the eyes was a normal color. Subcutaneous fatty tissue was poorly developed. Edemas and bedsores were not present. Submandibular, cervical and inguinal lymph nodes were enlarged to 0.5 cm, dense, and painless. Throat was slightly hyperemic, tonsils not enlarged. The frequency of respiratory movements was 18 per minute. During auscultation, wheezing was not present. Heart sounds were rhythmical, muffled. Abdomen was soft, sensitive along the intestine, peristalsis preserved. The liver edge had a soft-elastic consistency. Spleen was not enlarged. The stool was regular and liquid; color was brown without pathological impurities. Urination was free, painless. Diuresis was adequate. Neurological status: meningeal symptoms were absent.

Laboratory test data: The total blood test (08.25.16): leukocytes - 3.36×10⁹/l, erythrocytes - 5.5×10¹²/l, hemoglobin - 137 g/l, hematocrit - 39.3%, lymphocytes - 8%, monocytes - 8.3%, neutrophils - 82.5%, eosinophils - 1.2%, basophils - 0%, platelets - 89×10⁹/l, ESR - 32 mm/h.

Biochemical blood test (08.25.16): albumin - 34.5 g/l, ALT – 10 U/L, AST - 21.9 U/L, total bilirubin - 4 µmol/l, cholesterol - 2.01 mmol/l, creatinine - 79 µmol/l, glucose - 4.78 mmol/l, total protein - 80.9 g/l, urea - 4 mmol/l.

Cytomegalovirus (CMV) and Epstein Barr Virus (EBV) were detected in PCR (07.21.16). In PCR (07.21.16), the number of HIV RNA copies was 2, 400, 000 copies/ml.

Immunological examination of blood (07.19.16): leukocytes - 6.2×10⁹/l, lymphocytes 10% (19-37), CD3 - 41% (60-80), CD4 - 9% (55 cells/ml), SD8 - 30% (16-39).

EIA (08.25.2016): HbsAg - negative, anti-HBcorIgM - negative, anti-HbsAg - negative, HBeAg - negative, anti-HDV - negative, anti-HCV - positive, core (+), NS (-), anti-HCV IgM - negative.

CT chest (08.25.16): the disseminated lung process.

Ultrasound of the abdominal cavity (08.25.16): moderate lymphadenopathy, diffusive changes in the liver.

Blood for sterility and blood culture (08.26.16) was negative.

Smear from fauces for candidiasis (08.26.16): Candida albicans >1×10⁹/ml, sensitive to nystatinum.

PCR (08.26.16): CMV DNA was not detected, HSV RNA was not detected.

Sputum smear on MBT by the bactec method (08.29.16): MBTs were detected and resistant to streptomycin, isoniazid, rifampicin, kanamycin, and capreomycin. All sputum cultures were negative from September to December 2016.
MBT by the real-time PCR method (08.26.16): MBT resistant to rifampicin.

Based on clinical and anamnestic results of the examination, the following diagnosis was constructed: “HIV infection, 4B stage, the progression phase in the absence of ARVT. AIDS. Disseminated pulmonary TB in the phase of infiltration. MBT(+)”. MDR-TB: streptomycin, isoniazid, rifampicin, kanamycin, capreomycin. Candidiasis of the oral mucosa. Replicative chronic viral hepatitis C.”

On August 31, 2016, the patient was transferred with this diagnosis for treatment to the Department of Multiple Drug Resistance of the Yakut NPZ “Fitziatriia”, where she was treated for 75 days and received treatment according to the IV standard regime (pyrazinamide, ethambutol, amikacin, levofloxacin, cycloserine, para-aminosalicylic acid). The patient refused ARBT treatment. Due to side effects in the form of pain throughout the body, and weakness, aminosalicylic acid was replaced by prothionamide; ethambutol was canceled due to the contra-indication of the ophthalmologist. Patient was hospitalized again in March 2017 and underwent treatment according to the IV regime (levofloxacin, pyrazinamide, cycloserine, protonamide). She received only 12 doses. On a review of the chest X-ray (13.03.2017): The dynamics were positive; we detected a compaction of foci in S6 of both lungs. At the insistence of the patient, in connection with the move to another place of residence, she was discharged on 04.12.17, while the level of CD4 decreased up to 5.2 cells, the viral load was 3,350,000 copies/ml. Patient again refused ARBT treatment.

Conclusion

Resistant tuberculosis in HIV-infected patients with immunodeficiency is extremely difficult for effective treatment. Patients’ adherence to treatment also plays a significant role in recovery. Detection and treatment of tuberculosis in HIV-infected patients at an early stage of HIV infection is most effective. Nevertheless, our clinical case showed that the cure of tuberculosis is also possible in the late stages of HIV infection with the correct choice of treatment tactics, taking into account the resistance of MBT with the subsequent use of ARVT.

Thus, patients with HIV infection require professional psychological support with training and conversation. In our clinical case, the progression of HIV infection, against the background of the effective antituberculous therapy, is associated with the patient’s refusal to treat the underlying disease, which significantly worsens the prognosis.

Competing interests

The authors declare that they have no competing interests.

References